Press Releases

Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season

Media Update: RAD: Dupixent data reinforce use in atopic dermatitis patients with skin of color

Media Update: ISTH: new data highlight innovation from Sanofi’s pipeline in rare diseases

Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs

Press Release: Sanofi completes acquisition of DR-0201

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline

Media Update: ATS: Sanofi showcases leadership and breadth of scientific innovation in chronic inflammatory respiratory conditions

Press Release: Annual General Meeting of April 30, 2025

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

Media Update: Sanofi’s Foundation S and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD

Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis